Charles Schwab Investment Management Inc Denali Therapeutics Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,015,810 shares of DNLI stock, worth $21.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,015,810
Previous 1,059,304
4.11%
Holding current value
$21.8 Million
Previous $24.6 Million
20.3%
% of portfolio
0.01%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding DNLI
# of Institutions
227Shares Held
119MCall Options Held
60.6KPut Options Held
48.4K-
Baillie Gifford & CO13.3MShares$287 Million0.3% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$283 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$240 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$231 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$170 Million0.05% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.88B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...